| (Values in U.S. Thousands) | Sep, 2023 | Sep, 2022 | Sep, 2021 | Sep, 2020 | Sep, 2019 |
| Sales | 46,470 | 64,860 | 57,100 | 50,030 | 46,100 |
| Sales Growth | -28.35% | +13.59% | +14.13% | +8.52% | -8.48% |
| Net Income | -7,780 | 1,080 | 3,150 | 5,060 | 5,330 |
| Net Income Growth | -820.37% | -65.71% | -37.75% | -5.07% | +3.09% |
Qilian International Holding Group Ltd (QLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Qilian International Holding Group Limited is a pharmaceutical and chemical products manufacturer principally in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings and fertilizers. Qilian International Holding Group Limited is headquartered in Gansu, China.